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ABSTRACT
Background: Metabolic disturbances, obesity and lifeshortening cardiovascular morbidity are major clinical
problems among patients with antipsychotic treatment.
Especially two of the most efficacious antipsychotics,
clozapine and olanzapine, cause weight gain and
metabolic disturbances. Additionally, patients with
schizophrenia-spectrum disorders not infrequently
consume alcohol. Glucagon-like peptide-1 (GLP-1) has
shown to improve glycaemic control and reduce
alcohol intake among patients with type 2 diabetes.
Objectives: To investigate whether the beneficial
effects of GLP-1 analogues on glycaemic control and
alcohol intake, in patients with type 2 diabetes, can be
extended to a population of pre-diabetic psychiatric
patients receiving antipsychotic treatment.
Methods and analysis: Trial design, intervention
and participants: The study is a 16-week, doubleblinded, randomised, parallel-group, placebo-controlled
clinical trial, designed to evaluate the effects of the
GLP-1 analogue liraglutide on glycaemic control and
alcohol intake compared to placebo in patients who are
prediabetic, overweight (body mass index ≥27 kg/m2),
diagnosed with a schizophrenia-spectrum disorder and
on stable treatment with either clozapine or olanzapine.
Outcomes: The primary endpoint is the change in
glucose tolerance from baseline (measured by area
under the curve for the plasma glucose excursion
following a 4 h 75 g oral glucose tolerance test) to
follow-up at week 16. The secondary endpoints include
changes of dysglycaemia, body weight, waist
circumference, blood pressure, secretion of incretin
hormones, insulin sensitivity and β cell function, dualenergy X-ray absorption scan (body composition), lipid
profile, liver function and measures of quality of life,
daily functioning, severity of the psychiatric disease
and alcohol consumption from baseline to follow-up at
week 16. Status: Currently recruiting patients.
Ethics and dissemination: Ethical approval has
been obtained. Before screening, all patients will be
provided oral and written information about the trial.
The study will be disseminated by peer-review
publications and conference presentations.

Strengths and limitations of this study
▪ The study is a double-blinded, randomised, parallel-group, placebo-controlled clinical trial,
designed to evaluate the effects of the GLP-1
analogue liraglutide on glycemic control (measured by area under the curve for the plasma
glucose excursion following a 4 h 75 g oral
glucose tolerance test) in patients treated with
either clozapine or olanzapine.
▪ The study duration is only 16 weeks.
▪ The study has no third treatment arm for comparing liraglutide to one of the two established
add-on treatments for antipsychotic induced
weight gain and metabolic abnormalities–that is,
metformin or topiramate.
▪ The effect of liraglutide on alcohol consumption
is evaluated without requiring a certain weekly
minimum amount of alcohol consumption.

Trial registration number: ClinicalTrials.gov:
NCT01845259, EudraCT: 2013-000121-31.

INTRODUCTION
Metabolic disturbances, overweight and
obesity among patients with antipsychotic
treatment are major clinical problems,1 2
which most likely result from the interaction
of medication, genes and lifestyle factors,
such as physical inactivity and high fat diet.3
However, the mechanisms underlying antipsychotic metabolic adverse effects are
incompletely understood.4
Glucagon-like peptide-1 (GLP-1)-based
therapy was introduced to the market for
treatment of type 2 diabetes in 2006.5 GLP-1
is an incretin hormone, which is secreted
from endocrine L-cells of the small intestine
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in response to nutrients in the gut lumen.6 GLP-1 plays a
central role in the regulation of glycaemic control. It
conveys an insulinotropic effect via GLP-1 receptors on
the β cells of the pancreas and inhibits the secretion of
glucagon from the α cells of the pancreas, which together
lower the blood glucose level.7 Both of these effects are
strictly glucose dependent. The effects are more
pronounced at higher levels of blood glucose and the
effect ceases as blood glucose reaches values below
4–5 mmol/L.6 Therefore, stimulation of the GLP-1 receptor keeps the blood glucose at normal levels without
increasing the risk of hypoglycaemia.6 Naturally occurring
GLP-1 is rapidly degenerated within minutes by dipeptidyl
peptidase 4. Liraglutide, a GLP-1 receptor agonist
(GLP-1R), has a 97% homology with naturally occurring
GLP-1 hormone, but has a signiﬁcantly longer half-life
(12–14 h), which makes it useful for diabetic treatment.5
Antipsychotic medications are often associated with
body weight increase and metabolic disturbances.1–4
Psychiatric patients on antipsychotic treatment, especially those who are overweight or obese, and/or have
metabolic disturbances, are often encouraged to
increase physical activity. Studies including patients with
type 2 diabetes have shown that different types of exercise interventions with supervised training have positive
effects on glycaemic control.8 Exercise improves the
aerobic capacity and muscular strength, which is often
related to fat loss, increased muscle mass, increased cardiovascular ﬁtness and improved glycaemic control.
Exercise-induced fat loss and increase in muscle mass
may improve glycaemic control and insulin sensitivity in
those patients, even in the absence of an absolute
weight loss.8 However, in clinical practice, exercise interventions in patients with antipsychotic treatment have
often proven to be difﬁcult and may be without pronounced or sustained effect.9–11 Another possibility
includes instructions about healthier food intake. This
has proven efﬁcacious in some patients, but not in
others, and there exists a large group of patients, where
healthy lifestyle interventions have not proven to be very
efﬁcacious.9–11 In patients treated with a weightincreasing antipsychotic, another possibility would be to
shift treatment to a compound with less weightincreasing potential.12 13 However two of the most
potent weight-inducing antipsychotics, clozapine and
olanzapine, are also two of the most efﬁcacious antipsychotic compounds, and especially clozapine is often
used to treat patients resistant to other antipsychotics.14
Consequently, switching antipsychotic treatment is often
not possible in these cases.
In a recent meta-analysis of 32 studies on antiobesity
adjunction drug treatment, 13 different drug treatments
were investigated for a total of 1482 patients with
antipsychotic-related weight gain: metformin, nizatidine,
topiramate, amantadine, ﬂuoxetine, reboxetine, sibutramine, rosiglitazone, dextroamphetamine, d-fenﬂuramine,
famotidine, orlistat and metformin+sibutramine. Only ﬁve
of these agents were found to be superior to placebo, that
2

is, metformin, topiramate, fenﬂuramine, sibutramine and
reboxetine.15 Three of these compounds, fenﬂuramine,
sibutramine and reboxetine, have since been removed
from the market due to adverse effects leaving only two
evidence-based augmentation agents for clinical use, that
is, metformin and topiramate. Both compounds cause
approximately 2.5–3 kg weight loss compared to
placebo.15 Nevertheless, remarkably little is known about
metabolic advantages of these two add-on agents, and
most studies were small.15
Taken together, there exists a large and important
group of patients with antipsychotic treatment, who are
in urgent need for medical interventions to improve
their metabolic status, so that risk factors for lifeshortening cardiovascular morbidity can be reduced. In
this context, studies have shown that non-psychiatric
patients with type 2 diabetes treated with GLP-1R agonists improve body weight and glycaemic control.16 It is
of note, the idea to use metformin in patients with nondiabetes treated with antipsychotic was also triggered by
data showing that metformin was capable of mitigating
the weight-inducing effects of other antidiabetic medications in patients with diabetes.
In addition, patients with schizophrenia-spectrum disorders not infrequently have comorbid alcohol addiction.17 The well-established effect of GLP-1 analogues on
food reward seems to be driven by two key mesolimbic
brain structures, which are involved in the rewarding
properties of food as well as drugs of abuse, including
alcohol.18 To this effect, very recent preclinical data
demonstrated the inhibitory effects of the GLP-1R
exendin-4 on alcohol-mediated behaviour in rodents.18
Moreover, the GLP-1 analogue liraglutide was reported to
reduce alcohol intake in patients with type 2 diabetes.19
On the basis of the identiﬁed medical need and the
promising data of GLP-1R in patients with type 2 diabetes, we aim to investigate whether these beneﬁcial
ﬁndings on glycaemic control, and secondarily on
alcohol intake can be extended to psychiatric patients
treated with antipsychotics.

METHODS AND ANALYSIS
Overview
The present study is a 16-week, double-blinded, randomised, parallel-group, placebo-controlled clinical trial,
designed to evaluate the effects of liraglutide or placebo
in 100 patients, who are prediabetic, overweight (body
mass index (BMI), ≥27 kg/m2), diagnosed with a
schizophrenia-spectrum disorder and on stabile treatment with either clozapine or olanzapine. The trial will
be carried out at the Psychiatric Centre Copenhagen
and nearby psychiatric centres in close collaboration
with the Diabetes Research Division, Copenhagen
University Hospital Gentofte, Denmark. To be eligible
for participation in the study, patients will undergo a
pretreatment evaluation to screen them according to
inclusion and exclusion criteria.
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Inclusion criteria
▸ Age ≥18 and ≤65 years
▸ Clinical diagnosis of schizophrenia, schizotypal disorder
or paranoid psychosis according to the criteria of
International Classiﬁcation of Diseases (ICD10, WHO)
or the Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition (DSM-IV, the American
Psychiatric Association)
▸ Stable antipsychotic treatment with either clozapine
or olanzapine for at least 6 months (without dose
change for at least 30 days)
▸ Stable comedications for at least 30 days
▸ Stable weight (deﬁned as less than 5% change in
weight over the past 3 month before inclusion)
▸ BMI ≥27 kg/m2
▸ Dysglycaemia: impaired fasting glucose (IFG), that is,
fasting plasma glucose (FPG) level from 6.1 to
6.9 mmol/L and/or impaired glucose tolerance
(IGT), that is, 2 h glucose levels of 7.8 to 11 mmol/L
after a 75 g oral glucose tolerance test (OGTT) and a
FPG<7 mmol/L
▸ Informed oral and written consent
Exclusion criteria
▸ Type 1 or 2 diabetes with glycated haemoglobin
(HbA1c) >6.5%
▸ Compulsory treatment
▸ Women of childbearing potential who are pregnant,
breastfeeding or have intention of becoming pregnant
or are not using adequate contraceptive measures
▸ Participants treated with corticosteroids or other
hormone therapy (except oestrogens)
▸ Any active substance abuse or dependence for the
past 6 months (except for nicotine)
▸ Impaired hepatic function (liver transaminases >2
times upper normal limit)
▸ Impaired renal function (se-creatinine>150 μM and/
or macroalbuminuria)
▸ Impaired pancreatic function (acute or chronic pancreatitis and/or amylase >2 times upper normal limit)
▸ Cardiac problems deﬁned as decompensated heart
failure (NYHA class III or IV), unstable angina pectoris and/or myocardial infarction within the past
12 months
▸ Uncontrolled hypertension (systolic blood pressure
>180 mm Hg, diastolic blood pressure >100 mm Hg)
▸ Any condition that the investigator feels would interfere with trial participation
▸ Receiving any investigational drug within the past
3 months
▸ Use of weight-lowering pharmacotherapy within the
preceding 3 month
Patient enrolment and randomisation
It is estimated that a total of 150 patients, who are overdiagnosed
with
a
weight
(BMI≥27 kg/m2),
schizophrenia-spectrum disorder and on stable treatment
with either clozapine or olanzapine, will be screened.

The estimated screening failure rate is 15–20% and consequently we expect 125 patients to be randomised and
included in the study. The expected number of dropouts
is difﬁcult to estimate, since to our knowledge similar
interventions with daily subcutaneous injections have not
been performed before among psychiatric patients. In a
study by Astrup et al,7 16 of 90 patients (17.8%) in the liraglutide 1.8 mg group withdrew over the 20-week trial
period. We expect the withdrawal rate to be a little higher
in our patient population over time, but this effect is
most likely counteracted by the shorter study duration.
Consequently, we expect a dropout rate of maximum
20% in our study population over the 16- week trial
period, that is, a maximum of 25 of 125 patients will
dropout during 16 weeks of treatment resulting in about
100 patients completing the trial (see ﬁgure 1).
Completion or trial termination for any reason will be
fully documented in the Case Record Form. Patients are
free to withdraw from the trial at any time without
providing reason(s) for withdrawal and without prejudice to further treatment. The reason for withdrawal
could be a withdrawal of consent, treatment failure,
adverse event(s), pregnancy discovered during the trial,
signiﬁcant worsening (Clinical Global ImpressionsImprovement (CGI-I) score of 6 or 7 (much or very
much worse), change in the dosing of olanzapine or
clozapine of more than 20%, or loss to follow-up. Data
from dropouts will be included in data analysis. Patients
withdrawing from the trial should be encouraged to
undergo the same ﬁnal evaluations as patients completing the trial.
The study consists of a pretreatment evaluation, followed by a 16-week treatment period, where patients are
randomised to treatment with either daily subcutaneous
liraglutide or placebo. Patients will be randomised to
treatment with a 3 mL preﬁlled liraglutide pen-injector
containing 6 mg/mL liraglutide, or a 3 mL preﬁlled liraglutide placebo pen-injector. The randomisation will be
carried out by use of sealed opaque envelopes containing the randomisation code. Novo Nordisk will be
responsible for labelling and blinding the 3 mL preﬁlled
liraglutide pen-injector containing 6 mg/mL liraglutide
and the 3 mL preﬁlled liraglutide placebo pen-injector
before beginning the treatment period and for generating the randomisation code. An emergency code will be
kept at the Psychiatric Centre Copenhagen, allowing the
code to be broken if a patient develops an adverse reaction that requires knowledge of the treatment.
Treatment protocol
Before screening, all patients will be provided oral and
written information about the trial, including the most
common adverse events, and the procedures involved in
the study. The total duration of the trial for each patient
is 16 weeks. Each patient will attend regular visits (every
4 weeks) at the clinic in order to draw blood samples,
record changes in diet exercise and alcohol intake,
evaluate psychopathology ratings and side effects and
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Figure 1 Study flowchart.

measure body weight and waist circumference.
Antipsychotic medication and possible IGF/IGT/dysglycaemic history will also be obtained (see ﬁgure 1).
Blood analyses
At every visit, routine blood samples will be drawn, to
make sure that the patients do not have any serious
adverse effect to the treatment and to measure liver
function, triglycerides, cholesterol levels and HbA1c.
4

A 75 g-OGTT)
A 75 g OGTT will be performed at baseline and after
16 weeks of treatment in all participants. Seventy-ﬁve
grams of water-free glucose dissolved in 300 mL water is
to be ingested during the ﬁrst 5 min of the test. Blood is
sampled from a cannula inserted in an antecubital vein
before oral intake of the glucose load and at speciﬁc
times hereafter. At each time-point, blood is drawn for
serum/plasma analyses for glucose, insulin, c-peptide,
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glucagon, intact and total GLP-1 and GIP, respectively.
During both experimental days, the hand on the
cannula site is wrapped in a heating blanket (42°C)
throughout the test. Details are listed in table 1.
Dual-energy X-ray absorption scan
Dual-energy X-ray absorption (DEXA) scan will be performed at baseline and after 16 weeks of treatment in all
participants. The DEXA scan will be used to measure
total fat mass and fat percentage after 10 h of fasting, to
decrease large variations in hydration status.
Rating scales
To assess the level of psychopathology and alcohol use
during the trial, a number of different rating scales will
be used. The focus of the rating scales are, quality of life
(The Schizophrenia Quality of Life Scale (SQLS)), daily
functioning ( Global Assessment of Function (GAF)),
the disease severity (CGI—severity+improvement (CGI-S
+I)) and alcohol consumption (Alcohol Use Disorders
Identiﬁcation Test (AUDIT)).
Liraglutide treatment
Liraglutide/liraglutide placebo, 1.8 mg is administered
subcutaneously once daily from day 15 onwards for the
remainder of the treatment period after a 14-day ﬁxed
titration schedule (days 1–7: 0.6 mg liraglutide/liraglutide placebo; days 8–14: 1.2 mg liraglutide/liraglutide
placebo; day 15 and rest of the study: 1.8 mg liraglutide/
liraglutide placebo). Patients who do not tolerate
up-titration to 1.8 mg liraglutide will remain on the
highest tolerable dose of liraglutide. The patients are
instructed in injection technique. Compliance and
adverse events are noted during the entire period. If the
patient cannot self-inject the trial medication, an identiﬁed caregiver, also blinded to the treatment, will assist.

Non-pharmacological treatment
Throughout the trial, patients will receive oral and
written counselling about diet and exercise in accordance with the recommendations and guidelines from
The Danish National Board of Health (https://www.
sundhed.dk/borger/sundhed-og-livsstil/). Furthermore,
changes in diet and exercise will be recorded every
4 weeks during the trial.
Statistical analysis
All analyses will be performed using the modiﬁed
intention-to-treat principle on participants who were randomised and received at least one dose of the trial compound (liraglutide or liraglutide placebo). Missing data
will be imputed using the last-observation-carriedforward method. Analyses will be performed using SPSS,
with α set at 0.05 and two-sided testing.
All continuous outcomes, that is, change in metabolic
parameters, weight, body composition parameters,
alcohol use, etc, will be analysed using analysis of variance (ANOVA) from baseline to last observation endpoint. In case relevant baseline demographic, illness or
treatment parameters differ signiﬁcantly between the
two groups, these parameters will be included in an
ANOVA model. Categorical outcomes, that is, shift from
obesity, overweight, hyperglycaemia, hypertriglyceridaemia, etc, to the next lower risk category at last observed
endpoint, will be analysed using χ² analyses. In case relevant baseline demographic, illness or treatment parameters differ signiﬁcantly between the two groups, these
parameters will be included in a multivariate logistic
regression analysis model.
The primary outcome measure was used for the
sample size calculation. Based on unpublished data from
the study: “‘The Impact of Liraglutide on Glucose
Tolerance and the Risk of Type 2 Diabetes in Women

Table 1 Blood samples during OGTT
Time (min)

Plasma
glucose (mL)

GLP-1
(intact; mL)

GLP-1
(total; mL)

Glucagon (mL)

GIP (mL)

Insulin/c-peptide
(mL)

Extra
controls (mL)

−15
−10
0
5
10
15
20
30
40
50
60
90
120
150
180
240

0.200
0.200
0.200
0.200
0.200
0.200
0.200
0.200
0.200
0.200
0.200
0.200
0.200
0.200
0.200
0.200

0.700
0.700
0.700
0.700
0.700
0.700
0.700
0.700
0.700
0.700
0.700
0.700
0.700
0.700
0.700
0.700

1.4
1.4
1.4
1.4
1.4
1.4
1.4
1.4
1.4
1.4
1.4
1.4
1.4
1.4
1.4
1.4

1.4
1.4
1.4
1.4
1.4
1.4
1.4
1.4
1.4
1.4
1.4
1.4
1.4
1.4
1.4
1.4

2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2

4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4

3.5
3.5
3.5
3.5
3.5
3.5
3.5
3.5
3.5
3.5
3.5
3.5
3.5
3.5
3.5
3.5

GLP-1, glucagon-like peptide-1; OGTT, oral glucose tolerance test.
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With Previous Pregnancy-induced Diabetes,” the
expected baseline total area under the curve (AUC) for
the plasma glucose (PG) excursion following an OGTT,
an α of 5%, a power of 90%, and with values of 1695
(SD 158) in the intervention and 1800 (SD 158) in the
control group, the estimated sample size was 96 patients
(48 patients in each arm).
Endpoints
The primary endpoint
The primary endpoint is the change in glucose tolerance
from baseline (measured by AUC for the PG excursion
following a 4 h 75 g OGTT) to follow-up at week 16 or to
last observation, if study participation is stopped earlier.
The secondary endpoints
Secondary endpoints include changes of dysglycaemia
(IFG, IGT, combined IFG/IGT or diabetes), changes in
body weight, waist circumference, blood pressure, secretion of incretin hormones, insulin sensitivity and β cell
function, evaluated by homoeostatic model assessment,
DEXA scan (body composition), lipid proﬁle, liver function and measures of quality of life, daily functioning,
severity of the psychiatric disease and alcohol consumption (in patients with alcohol consumption at baseline)
from baseline to follow-up at week 16 or to last observation, if study participation is stopped earlier.
Dissemination
Before screening, all patients will be provided oral and
written information about the trial, including the most
common adverse events, and the procedures involved in
the study.
We considered a longer trial than 16 weeks in order to
determine the longer term effects of liraglutide on body
weight and metabolic status. However, this would likely
have resulted in a higher sample size as dropout rates
increase with the duration of the trial. In addition,
recruitment could have been affected too, as patients
may be less likely to commit for a longer term study. We
also considered following patients after stopping the
treatment at 16 weeks, in order to assess the durability
and speed of the loss of efﬁcacy. However, this would
have increased the budget and would be premature, as
we believe that this information is only valuable once a
signiﬁcant beneﬁt of liraglutide has been established.
We further considered adding a third arm and comparing liraglutide to one of the two established add-on treatments for antipsychotic-induced weight gain and
metabolic abnormalities, that is, metformin or topiramate. However, adding a third arm would have increased
the complexity and cost of the trial considerably and we
considered this also premature, as efﬁcacy of liraglutide
would have to be demonstrated ﬁrst before considering
an active comparator trial.
A deﬁnite weakness of this study is the need for the
daily subcutaneous injection of liraglutide. However, this
is a proof of concept study. Should robust efﬁcacy be
6

demonstrated, this would provide the necessary stimulus
to invest in the development of an orally administered
formulation of liraglutide or a related GLP-1 analogue.
A further weakness is that we will assess the effect of liraglutide on alcohol consumption without requiring a
minimum alcohol-intake in all participants. Although
this will reduce the power to show an effect, the change
in alcohol consumption is only a secondary outcome
and restricting participants to those using alcohol would
have reduced eligible patients for this study. Moreover,
we also deliberately excluded patients with substance
abuse or addition, as marked alcohol use can interfere
with the primary outcome, insulin resistance, and as substance abuse has been associated with decreased treatment adherence.
CONCLUSIONS
The present trial aims to evaluate the effects on glycaemic control following 16 weeks of treatment with liraglutide or placebo in 100 patients, who are prediabetic,
overweight, diagnosed with a schizophrenia-spectrum
disorder and on treatment with either clozapine or olanzapine. Results of this ﬁrst study of its kind are expected
to determine whether liraglutide is effective in improving dysglycaemia and other metabolic parameters as well
as alcohol use in patients on antipsychotic medication.
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